Verbatim response from ChatGPT
Short version
- After demand for GLP‑1 weight‑loss and diabetes drugs (semaglutide, tirzepatide, etc.) surged, many compounding pharmacies started making and marketing compounded versions.
- The FDA concluded in 2023–2024 that a lot of that activity violated the law (mass‑marketing compounded copies, using unvetted bulk active pharmaceutical ingredients, and not meeting required manufacturing controls). The agency issued safety advisories, warning letters, and increased enforcement against pharmacies that were compounding and distributing GLP‑1 products improperly.
- Compounded GLP‑1s can still be legal, but only when made under the limits of the compounding laws and regulations (see below). Many of the retail operations that were advertising mass‑market compounded GLP‑1s were told to stop.
What the FDA’s position and actions were (high level)
- The FDA warned that compounding from bulk APIs (active ingredients) and producing essentially copies of FDA‑approved drugs for general sale is unlawful in most cases. They also flagged safety risks from unverified supply chains and inadequate quality controls.
- The agency issued warning letters and pursued regulatory action against specific facilities that appeared to be producing and selling compounded GLP‑1s at scale or without proper oversight.
- The message was: patient‑specific compounding done by licensed pharmacists/physicians can be legal; mass production, use of unapproved bulk sources, or circumventing FDA‑approved products is not.
Why some compounding operations were targeted
- Many operations were: advertising broadly on social media; selling to consumers without a patient‑specific prescription; using bulk APIs from overseas suppliers with uncertain quality; or not following good manufacturing practices. Those are the exact behaviors the FDA has warned against.
Who can still operate legally (and how to get GLP‑1s safely)
- Licensed pharmacies filling individually‑prescribed, patient‑specific compounded GLP‑1 preparations under state board rules (commonly called 503A compounding) — but only if they comply with state law and source ingredients lawfully and provide appropriate quality controls.
- Registered outsourcing facilities (so‑called 503B facilities) that are registered with the FDA and operate under cGMP may legally compound drugs in larger batches — but even 503B facilities are limited and generally may not produce copies of FDA‑approved products for routine commercial distribution unless specific conditions are met.
- The safest, most straightforward legal route is to use FDA‑approved GLP‑1 products prescribed by a licensed clinician and dispensed through licensed pharmacies or manufacturer specialty programs. Examples:
- Novo Nordisk — Ozempic, Wegovy, Rybelsus (semaglutide) and Novo’s patient support resources
- Eli Lilly — Mounjaro, Zepbound (tirzepatide) and Lilly patient support
- Fill prescriptions at major licensed pharmacies or accredited specialty pharmacies (CVS, Walgreens, Walmart, OptumRx, Accredo, Diplomat/Optum Specialty, etc.) or through manufacturer specialty pharmacy programs.
- Avoid buying GLP‑1 injections from Instagram/marketplace ads, overseas sellers, or any source that won’t provide a valid prescription, lot/batch testing (Certificate of Analysis), or state pharmacy license information.
How to check whether a pharmacy/compounder is legal
- Ask the pharmacy for: state pharmacy license number, whether they are a registered 503B outsourcing facility (if applicable), and Certificates of Analysis for APIs/batches.
- Check your state board of pharmacy for the pharmacy’s license status.
- Check the FDA’s list of registered 503B outsourcing facilities (if you’re dealing with a larger compounder).
- Prefer NABP/VIPPS‑accredited or URAC‑accredited pharmacies for online purchases.
If you want help
- If you have a specific pharmacy, telehealth service, or ad you’re worried about, tell me the name and I can help verify whether it appears legitimate and point you to the right places to check.